For Healthcare Professionals: Multimedia

Memorial Sloan-Kettering surgeons describe a phase II trial comparing agents administered through HIPEC for cancers of the appendix, colon, and rectum.

Medical oncologist Michael Morris describes a technique developed at Memorial Sloan-Kettering to image prostate cancer metastases via PET scan.

Medical oncologist Michael Morris describes noninvasive radiopharmaceuticals for prostate cancer–related bone metastases.

The majority of cancer patients use complementary therapies such as herbs and dietary supplements. Although figures differ, surveys indicate that as many as 60 percent of people with cancer take two or more dietary supplements daily.

Gynecologic oncologist Dennis Chi describes a clinical trial evaluating secondary cytoreduction with and without HIPEC for various malignancies.

Medical oncologist Gary Schwartz explains promising results of a phase II trial examining a novel combination of agents in patients with soft tissue and bone sarcomas.

Medical oncologists Marcel van den Brink and Miguel-Angel Perales describe results of a phase I trial of IL-7 in stem cell transplantation.

Medical oncologist Marcel van den Brink explains that functioning T cells may be generated in abdominal lymph nodes following allogeneic bone marrow transplant.

Fellow Parastoo Dahi describes study results indicating that higher resolution HLA matching is possible without significantly compromising graft dose in unrelated cord blood transplantation.

Medical oncologist David Ilson talks about advances in adjuvant therapies for gastric cancer in a Grand Rounds presentation.

Medical oncologist Virginia Klimek discusses a randomized clinical trial for patients with myelodysplastic syndromes (MDS) and symptomatic anemia. The standard treatments for MDS include red blood cell transfusions and erythropoietin injections, but many patients do not respond well to these therapies. Memorial Sloan-Kettering Cancer Center is participating in a multicenter Eastern Cooperative Oncology Group study that is assessing the effectiveness of combining lenalidomide with erythropoietin injections.

Gynecologic oncologist Dennis Chi reviews the use of minimally invasive techniques such as laparoscopy for the surgical staging of ovarian cancer.

Medical oncologist William Tap discusses a multicenter randomized study that compares doxorubicin plus TH-302 versus doxorubicin alone for locally advanced soft tissue sarcoma that is inoperable or metastatic.

Thoracic surgeon Inderpal Sarkaria discusses advances that have enabled surgeons to treat some esophageal cancers with robotics.

Urologic surgeon Jonathan Coleman discusses an irreversible electroporation, a focal therapy that employs a NanoKnife® device to deliver an electrical current to small, localized prostate tumors.

Urologic surgeon Jonathan Coleman discusses focal cryoablation to destroy small and localized prostate tumors.

Urologic surgeon Jonathan Coleman discusses approaches and techniques that have enabled surgeons to perform many kidney procedures in a less invasive manner.

Thoracic surgeon Inderpal Sarkaria discusses a clinical trial comparing quality of life after minimally invasive versus open esophagectomy.

Hematologist-oncologist Ellin Berman discusses a randomized phase III clinical trial of an investigational oral drug, sapacitabine, for AML in elderly patients.

Integrative medicine physician Gary Deng discusses complementary therapies for managing chronic pain.

Gynecologic oncologist Elizabeth Jewell discusses the fluorescent dye surgical platform in sentinel lymph node mapping for cervical and endometrial cancer detection.

Gastrointestinal Oncology Service Chief Leonard Saltz talks about advances in the personalized treatment and cure of rectal cancer in this Grand Rounds presentation.

Nancy Kemeny, MD, discusses hepatic arterial infusion therapy for the treatment of liver metastases.

Chief of the Lymphoma Service Andrew Zelenetz discusses a retrospective review examining the frequency of FDG avidity across a range of lymphoma histologies.

Thrombocytopenia is a common effect of cytotoxic chemotherapy regimens in cancer patients, often necessitating reduction or delay in subsequent cycles. While the thrombocytopenia typically resolves with time, a subset of patients with chemotherapy-induced thrombocytopenia (CIT) have prolonged thrombocytopenia, of idiopathic etiology, that interferes with subsequent treatment.

Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses positive responses of brentuximab vedotin in patients with Hodgkin lymphoma and systemic ALCL.

Medical Director of the Cytotherapy Laboratory Guenther Koehne discusses WT1-specific cellular immune responses in patients with relapsed multiple myeloma and high-risk cytogenetics.

Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses relationship between DLT and SAE with increasing age and comorbidities in lymphoma trials.

Medical oncologist Omar Abdel-Wahab discusses studies that assessed the functional implications of ASXL1 mutations in the hematopoietic compartment.

Medical oncologist Omar Abdel-Wahab discusses a study that validates a lower-risk prognostic scoring system’s ability to identify higher-risk MDS patients.

Martin Tallman, a hematologist-oncologist at Memorial Sloan-Kettering, discusses a clinical trial combining arsenic trioxide with all-tansretinoic acid (ATRA) for the treatment of patients with APL.

Bernard Bochner discusses approaches to bladder cancer treatment.

MSKCC scientists are engineering immune-system cells called T cells so that they can identify and destroy leukemia and prostate cancer cells.

Genitourinary cancer expert Robert Motzer discusses new treatment options for patients with advanced renal cell carcinoma.

Medical oncologist Dean Bajorin describes novel chemotherapy drugs in development at Memorial Sloan-Kettering that may be given before bladder cancer surgery.